CCEL (Cryo-Cell International) Cyclically Adjusted Revenue per Share: $4.44 (As of May. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CCEL Cryo-Cell International Inc CCEL
58 GF Score
Price $3.70
GF Value $5.45
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Cryo-Cell International Cyclically Adjusted Revenue per Share?

Cryo-Cell International CCEL +3.93% 58 Cyclically Adjusted Revenue per Share is $4.44 as of May. 2026. GuruFocus rates CCEL with a GF Score™ of 58/100 and a GF Value™ of $5.45 (Possible Value Trap). The stock has 4 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Cryo-Cell International's adjusted revenue per share for the three months ended in May. 2026 was $0.965. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $4.44 for the trailing ten years ended in May. 2026.

During the past 12 months, Cryo-Cell International's average Cyclically Adjusted Revenue Growth Rate was 5.70% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 6.20% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 8.60% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 9.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Cryo-Cell International was 20.40% per year. The lowest was 6.00% per year. And the median was 10.35% per year.

As of today (2026-08-05), Cryo-Cell International's current stock price is $3.70. Cryo-Cell International's Cyclically Adjusted Revenue per Share for the quarter that ended in May. 2026 was $4.44. Cryo-Cell International's Cyclically Adjusted PS Ratio of today is 0.83.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Cryo-Cell International was 4.64. The lowest was 0.65. And the median was 2.41.


Cryo-Cell International  (AMEX:CCEL) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Cryo-Cell International's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=3.70/4.44
=0.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Cryo-Cell International was 4.64. The lowest was 0.65. And the median was 2.41.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Cryo-Cell International Cyclically Adjusted Revenue per Share Related Terms


Cryo-Cell International Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Cryo-Cell International's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cryo-Cell International Cyclically Adjusted Revenue per Share Chart

Cryo-Cell International Annual Data
Trend Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22 Nov23 Nov24 Nov25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.18 3.56 3.82 4.06 4.27

Cryo-Cell International Quarterly Data
Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26 May26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.20 4.25 4.27 4.32 4.44

CCEL vs EHSI, PIII, CCM: Cyclically Adjusted Revenue per Share Comparison

For the Medical Care Facilities subindustry, Cryo-Cell International's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cryo-Cell International Cyclically Adjusted PS Ratio vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Cryo-Cell International's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Cryo-Cell International's Cyclically Adjusted PS Ratio falls into.


CCEL
58GF Score
Cryo-Cell International Inc CCEL
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cryo-Cell International Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Cryo-Cell International's adjusted Revenue per Share data for the three months ended in May. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of May. 2026 (Change)*Current CPI (May. 2026)
=0.965/335.1230*335.1230
=0.965

Current CPI (May. 2026) = 335.1230.

Cryo-Cell International Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201608 0.835 240.849 1.162
201611 0.862 241.353 1.197
201702 0.777 243.603 1.069
201705 0.807 244.733 1.105
201708 0.885 245.519 1.208
201711 0.850 246.669 1.155
201802 0.877 248.991 1.180
201805 0.824 251.588 1.098
201808 0.940 252.146 1.249
201811 1.102 252.038 1.465
201902 0.890 252.776 1.180
201905 0.965 256.092 1.263
201908 0.974 256.558 1.272
201911 0.953 257.208 1.242
202002 0.938 258.678 1.215
202005 0.970 256.394 1.268
202008 0.992 259.918 1.279
202011 0.926 260.229 1.193
202102 0.837 263.014 1.066
202105 0.871 269.195 1.084
202108 0.863 273.567 1.057
202111 0.855 277.948 1.031
202202 0.830 283.716 0.980
202205 0.892 292.296 1.023
202208 0.914 296.171 1.034
202211 0.912 297.711 1.027
202302 0.927 300.840 1.033
202305 0.938 304.127 1.034
202308 0.950 307.026 1.037
202311 0.951 307.051 1.038
202402 0.951 310.326 1.027
202405 0.977 314.069 1.042
202408 0.987 314.796 1.051
202411 0.987 315.493 1.048
202502 0.972 319.082 1.021
202505 0.976 321.465 1.017
202508 0.969 323.976 1.002
202511 0.974 324.122 1.007
202602 0.954 326.785 0.978
202605 0.965 335.123 0.965

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $4.44 mean?
Cryo-Cell International (CCEL) has a Cyclically Adjusted Revenue per Share of $4.44 as of May. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Cryo-Cell International and its competitors.
Is Cryo-Cell International's Cyclically Adjusted Revenue per Share too high?
Cryo-Cell International's current Cyclically Adjusted Revenue per Share is $4.44. Overall, Cryo-Cell International has a GF Score™ of 58/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Cryo-Cell International's Cyclically Adjusted Revenue per Share compare to EHSI and PIII?
Cryo-Cell International's Cyclically Adjusted Revenue per Share of $4.44 can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Healthcare Providers & Services company?
A good Cyclically Adjusted Revenue per Share depends on the Healthcare Providers & Services industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Cryo-Cell International and its competitors. Cryo-Cell International's current Cyclically Adjusted Revenue per Share is $4.44. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cryo-Cell International stock overvalued right now?
Based on GuruFocus' analysis, Cryo-Cell International (CCEL) is currently considered Possible Value Trap. The stock's GF Value™ is $5.45, compared to a current price of $3.70 — trading 32.1% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is $4.44. Cryo-Cell International's overall GF Score™ is 58/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Cryo-Cell International (CCEL), the current Cyclically Adjusted Revenue per Share is $4.44 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cryo-Cell International (CCEL) Overvalued in 2026?

Based on GuruFocus' analysis, Cryo-Cell International stock appears to be undervalued. The current stock price of $3.70 is trading 32.1% below its estimated GF Value™ of $5.45. GuruFocus considers Cryo-Cell International to be Possible Value Trap.

Key valuation signals for CCEL:

  • Cyclically Adjusted Revenue per Share: $4.44
  • GF Value™: $5.45 vs. price of $3.70 (32.1% below fair value)
  • GF Score™: 58/100 with 4 warning signs

No single metric tells the full story. See the CCEL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cryo-Cell International Business Description

Other Exchanges ZCY:Germany
Address 700 Brooker Creek Boulevard, Suite 1800, Oldsmar, FL, USA, 34677
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.
58GF Score

Get the complete analysis for CCEL

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.70
Price
$5.45
GF Value